Ending the evidence gap for pregnancy, HIV and co-infections: ethics guidance from the PHASES project.

Abstract

INTRODUCTION:

While pregnant people have been an important focus for HIV research, critical evidence gaps remain regarding prevention, co-infection, and safety and efficacy of new antiretroviral therapies in pregnancy. Such gaps can result in harm: without safety data, drugs used may carry unacceptable risks to the foetus or pregnant person; without pregnancy-specific dosing data, pregnant people face risks of both toxicity and undertreatment; and delays in gathering evidence can limit access to beneficial next-generation drugs. Despite recognition of the need, numerous barriers and ethical complexities have limited progress. We describe the process, ethical foundations, recommendations and applications of guidance for advancing responsible inclusion of pregnant people in HIV/co-infections research.

DISCUSSION:

The 26-member international and interdisciplinary Pregnancy and HIV/AIDS: Seeking Equitable Study (PHASES) Working Group was convened to develop ethics-centred guidance for advancing timely, responsible HIV/co-infections research with pregnant people. Deliberations over 3 years drew on extensive qualitative research, stakeholder engagement, expert consultation and a series of workshops. The guidance, initially issued in July 2020, highlights conceptual shifts needed in framing research with pregnant people, and articulates three ethical foundations to ground recommendations: equitable protection from drug-related risks, timely access to biomedical advances and equitable respect for pregnant people's health interests. The guidance advances 12 specific recommendations, actionable within the current regulatory environment, addressing multiple stakeholders across drug development and post-approval research, and organized around four themes: building capacity, supporting inclusion, achieving priority research and ensuring respect. The recommendations describe strategies towards ethically redressing the evidence gap for pregnant people around HIV and co-infections. The guidance has informed key efforts of leading organizations working to advance needed research, and identifies further opportunities for impact by a range of stakeholder groups.

CONCLUSIONS:

There are clear pathways towards ethical inclusion of pregnant people in the biomedical research agenda, and strong agreement across the HIV research community about the need for - and the promise of - advancing them. Those who fund, conduct, oversee and advocate for research can use the PHASES guidance to facilitate more, better and earlier evidence to optimize the health and wellbeing of pregnant people and their children.

• Authors: Anne Drapkin Lyerly, Richard Beigi, Linda-Gail Bekker, Benjamin H Chi, Susan E Cohn, Dázon Dixon Diallo, Joseph Eron, Ruth Faden, Elana Jaffe, Angela Kashuba, Mary Kasule, Carleigh Krubiner, Maggie Little, Joseph Mfustso-Bengo, Lynne Mofenson, Victor Mwapasa, Lillian Mworeko, Landon Myer, Martina Penazzato, Annette Rid, Roger Shapiro, Jerome Amir Singh, Kristen Sullivan, Marissa Vicari, Jacque Wambui, Amina White, Marisha Wickremsinhe, Leslie Wolf
• Journal: Journal of the International AIDS Society (J Int AIDS Soc) Vol. 24 Issue 12 Pg. e25846 (12 2021) ISSN: 1758-2652 [Electronic] Switzerland
• PMID: 34910846 (Publication Type: Journal Article, Research Support, N.I.H., Extramural)
• Copyright: © 2021 The Authors. Journal of the International AIDS Society published by John Wiley & Sons Ltd on behalf of the International AIDS Society.

Topics

• Acquired Immunodeficiency Syndrome
• Biomedical Research
• Child
• Coinfection
• Female
• HIV Infections (drug therapy, prevention & control)
• Humans
• Pregnancy
• Stakeholder Participation